Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Phase 1 Recruiting 217 enrolled Ono Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Timeline

Start: 2021-12-10
Primary completion: 2027-08-31
Completion: 2028-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ONO-4685	Unknown	—	Intravenous

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Summary

Timeline

Drugs

Indications